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Introduction: Glucose measurement in intensive care medicine is performed intermittently with the risk of
undetected hypoglycemia. The workload for the ICU nursing staff is substantial. Subcutaneous continuous glucose
monitoring (CGM) systems are available and may be able to solve some of these issues in critically ill patients.
Methods: In a randomized controlled design in a mixed ICU in a teaching hospital we compared the use of
subcutaneous CGM with frequent point of care (POC) to guide insulin treatment. Adult critically ill patients with
an expected stay of more than 24 hours and in need of insulin therapy were included. All patients received
subcutaneous CGM. CGM data were blinded in the control group, whereas in the intervention group these data
were used to feed a computerized glucose regulation algorithm. The same algorithm was used in the control
group fed by intermittent POC glucose measurements. Safety was assessed with the incidence of severe
hypoglycemia (<2.2 mmol/L), efficacy with the percentage time in target range (5.0 to 9.0 mmol/L). In addition,
we assessed nursing workload and costs.
Results: In this study, 87 patients were randomized to the intervention and 90 to the control group. CGM device
failure resulted in 78 and 78 patients for analysis. The incidence of severe glycemia and percentage of time within
target range was similar in both groups. A significant reduction in daily nursing workload for glucose control was
found in the intervention group (17 versus 36 minutes; P <0.001). Mean daily costs per patient were significantly
reduced with EUR 12 (95% CI −32 to −18, P = 0.02) in the intervention group.
Conclusions: Subcutaneous CGM to guide insulin treatment in critically ill patients is as safe and effective as
intermittent point-of-care measurements and reduces nursing workload and daily costs. A new algorithm designed
for frequent measurements may lead to improved performance and should precede clinical implementation.
Trial registration: Clinicaltrials.gov, NCT01526044. Registered 1 February 2012.Introduction
Stress-induced hyperglycemia is common and relates to
adverse outcomes in critically ill patients [1,2]. The out-
comes of two large intervention studies are in some way
contradictory but the consensus is that hyperglycemia
should be corrected, while avoiding hypoglycemia and* Correspondence: phjvdvoort@chello.nl
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unless otherwise stated.high glucose variability [3-8]. On the basis of the avail-
able evidence, it seems preferable to maintain a blood
glucose level around 8.0 mmol/L for the majority of
critically ill patients [9,10].
Glucose regulation regimens require frequent monitor-
ing of glucose, which leads to a considerable workload
for the intensive care (IC) nurses. In addition, glucose
regulation carries an inherent risk of insulin-induced
hypoglycemia, which is associated with mortality [6].
Information about the glucose level is lacking for thetd. This is an Open Access article distributed under the terms of the Creative
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hypoglycemic episodes. Continuous glucose monitoring
(CGM) could be of value to facilitate or improve glycemic
control. Previous studies have indicated an acceptable
accuracy and reliability for subcutaneous CGM devices in
critically ill patients [11-15]. The only prospective ran-
domized controlled trial so far that assessed the role for
CGM in glycemic control in critically ill patients showed
that real-time CGM increased the safety of tight glycemic
control in critically ill patients by significantly reducing
severe hypoglycemic events [16]. However, an improve-
ment of the mean glucose concentration by using real-
time CGM was not found [16].
Thus, CGM may give us the ability to detect early
(possible) hypo- and hyperglycemia as well as minimiz-
ing swings in glucose levels. Moreover, the use of CGM
may facilitate the process of glycemic control and may
reduce the number of blood samples and accompanying
blood loss, nursing workload and costs. To date, there
are few data available how CGM-driven glucose regula-
tion compares to point-of-care (POC) -driven glucose
regulation and no controlled studies specifically evalu-
ated workload and cost of CGM. The aim of the present
study was to assess the safety, efficacy, workload and
costs of a subcutaneous CGM system-guided blood glu-
cose regulation in comparison with frequent POC blood
glucose-guided regulation in a mixed population of crit-
ically ill patients.
Material and methods
Study design and participants
This was a randomized controlled open-label clinical
trial, performed in a 20-bed mixed medical-surgical
ICU of a teaching hospital (Onze Lieve Vrouwe Gasthuis,
Amsterdam, the Netherlands). Patients were recruited
over a period of 18 months from 2011 till late 2012.
Patients were eligible for inclusion within 24 hours
after ICU admission if they were 18 years or older, in
need of intravenous (i.v.) insulin treatment for glucose
regulation and with an expected length of stay in the
ICU of at least 24 hours. Patients could not be in-
cluded if any of the following criteria was present:
lack of informed consent, participation in another
trial or previous participation in this trial or when a
CGM system was currently not available. The study
ended when patients were discharged from the ICU
or because of technical failure of the CGM device.
The maximum study duration was set at five days for
both treatment groups. The complete nursing staff
was trained beforehand to handle all devices used in
this study adequately. This study was approved by the
ethics committee VCMO, Nieuwegein, The Netherlands
and was in line with Dutch and European legislation.
All patients or their legal representative provided writteninformed consent. This trial is registered with Clinicaltrials.
gov, number NCT01526044.
Randomization
Patients who met the inclusion criteria were randomized
in a 1:1 ratio with computerized block randomization to
either the intervention group or the control group.
Study procedures
Algorithm
In all study participants, blood glucose regulation was
performed by a sliding scale algorithm with a blood glu-
cose target of 5.0 to 9.0 mmol/L, which was integrated
into the patient data management system (PDMS, Meta-
Vision; iMDsoft, Tel Aviv, Israel) [17]. Hypoglycemia was
defined as a blood glucose level of <2.2 mmol/L in line
with the Van den Berghe trial [3]. Below target was
defined as a glucose level from 2.2 mmol/L till the lower
target level of 5.0 mmol/L. Above target, all glucose
levels were above 9.0 mmol/L. The algorithm instructed
the insulin i.v. infusion rate (or glucose administration
in case of hypoglycemia) after each glucose measure-
ment. The time for the next glucose measurement was
also defined from the algorithm and depended on the
stability of the glucose level over time.
Glucose measurement
Study participants allocated to the intervention group re-
ceived a subcutaneous CGM system (FreeStyle Navigator™,
Abbott Diabetes Care, Alameda, CA, USA), which was
used to guide blood glucose regulation. The nurses were
trained to insert the subcutaneous glucose sensors on the
patients’ abdomen or upper arm. After insertion of the
subcutaneous sensor, a transmitter was attached that con-
nects through wireless communication to a receiver, which
displays the real-time glucose readings every minute and
stores glucose readings every 10th minute. The CGM
system needed a one-hour stabilization period, in which
glucose measurements were not performed. Calibration of
the system using an arterial blood sample was performed
five times in total, after 1, 2, 8 to 10, 24 to 32 and 72 to
80 hours, following manufacturer instructions. The CGM
system sounded an alarm when additional calibrations
were needed. On the times that the algorithm needed a
new glucose measurement, the readings from the CGM
system were entered in the computerized glucose regula-
tion protocol that was embedded in the PDMS. Other
CGM values were not used in the algorithm. The CGM
system sounded an alarm when the glucose level was
either <5.0 mmol/L or >9.0 mmol/L. When this occurred,
the nurse entered this additional glucose level in the com-
puterized protocol, which triggered the glucose algorithm
to advise an insulin dosing adjustment. The CGM repea-
ted its alarm after 15 minutes when the glucose level was
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into the system and dose adjustments were made until
target range was achieved. Every hypoglycemic event
(<2.2 mmol/L) needed to be verified by an arterial blood
glucose sample. In case of a discrepancy between the
CGM value and the arterial blood glucose sample, the
latter was leading in clinical decision-making.
Blood glucose regulation in the study participants
allocated to the control group was performed by use of
frequent point-of-care (POC) measurements using Accu-
Chek™ (Roche/Hitachi, Basel, Switzerland). All blood sam-
ples were obtained from an indwelling arterial catheter.
The displayed glucose levels were automatically stored in
the PDMS. Participants in the control group also received
a subcutaneous Freestyle Navigator CGM system, how-
ever, these data were blinded and not used for blood glu-
cose regulation. Calibrations were performed following
manufacturer instructions and no alarms were set.
In both groups arterial reference blood glucose sam-
ples were drawn six times daily at standardized times
and analyzed by the ABL Flex automated blood gas
analyzer (BGA) (Radiometer, Copenhagen, Denmark).
These values were automatically stored into the PDMS
but were blinded to both nurses and physicians.
Study endpoints
The primary safety outcome was the incidence of severe
hypoglycemia (<2.2 mmol/L) during the intervention. Effi-
cacy outcomes were the percentage of time that glucose
levels were within the target range (5.0 to 9.0 mmol/L),
below target range (2.2 to 5.0 mmol/L), and in the hyper-
glycemic range (>9.0 mmol/L). In addition, mean blood
and sensor glucose levels and glucose variability defined
as the mean absolute glucose (MAG) change (ΔGlucose/
ΔTime) were endpoints too [8]. The accuracy of the CGM
and the POC device was assessed by calculating the me-
dian relative absolute deviation (RAD) between reference
glucose and CGM or POC glucose.
Nursing workload for glucose control per day was
determined by the number of POC measurements or
measurements from the sensor, which were entered in
the computerized glucose regulation protocol and the
amount of calibrations of the CGM sensor (in the inter-
vention group only). A time-in-motion design was used
to estimate the time that it took to execute targeted
glucose control and insulin treatment per group. The
following subtasks were observed: (1) POC measurement
(this included the initiation, blood sampling, blood testing
and processing), (2) sensor placement, (3) sensor calibra-
tion and (4) time needed to determine a CGM value and
entering the value in the decision support module. The
tenfold-recorded elapsed times per subtask were averaged
and then multiplied by the 24-hour blood sample average
collected from the clinical trial.Cost analysis was performed from a health-care payer
perspective with a one-day (24 hours) time horizon. The
outcome measure in the economic evaluation was the
costs per patient for glycemic control in 24 hours. Cost
parameters included nursing personnel costs, device
costs, materials needed for glucose monitoring and la-
boratory costs. Cost estimates for the parameters were
derived from the hospital and laboratory ledger, devices
manufacturers’ data and the Dutch guide for health eco-
nomic research [18]. Costs are expressed in euros and
are based on the year 2013. Because of the short time
horizon of this analysis (24 hours), the costs were not
discounted.
Data collection
Clinical and laboratory baseline data were extracted
from the PDMS after randomization: demographic data,
body mass index (BMI), reason for ICU admission,
history of diabetes, history of renal failure, severity of
disease scores (the sequential organ failure assessment
(SOFA) score and acute physiology and chronic health
evaluation (APACHE IV) score at admission), blood
glucose levels at admission and the use of mechanical
ventilation. Blood glucose data, that is reference arterial
blood glucose samples and glucose values that were
entered in the decision support module (CGM measure-
ments in the intervention group, POC measurements in
the control group) were also extracted from the PDMS.
Continuous glucose data from the CGM device were
uploaded to a computer using CoPilot™ Health Manage-
ment System for FreeStyle Navigator (Abbott Diabetes
Care, Alameda, CA, USA) and entered in the study data-
base. All reference glucose measurements were linked by
time with the concomitant CGM measurements and
Accu-Chek measurements.
Statistical analysis
A sample size of 160 (80 participants in each group)
conferred 80% power, with two-sided P = 0.05, to detect
an absolute difference of 10% in the incidence of severe
hypo- or hyperglycemia between the intervention and
the control group. A total sample size of 178 patients
(89 patients per group) is needed to correct for an ex-
pected 10% drop out. Results are expressed as percentages
for categorical variables, mean and standard deviation
(SD) for continuous normally distributed variables, and
median and interquartile range (IQR) for continuous non-
normally distributed variables. Groups were compared by
using Fisher’s exact test, Student’s t test or Mann-Whitney
rank-sum test as appropriate. Median RAD was calculated
instead of mean because of its skewed distribution. Costs
were calculated as the summed product of factors and
resources used and their respective unit costs and were
averaged per patient per day. Because of skewed (cost)
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95% confidence intervals for the mean differences follow-
ing bias-corrected and accelerated nonparametric boot-
strapping, that is drawing 1,000 samples of the same size
as the original sample separately for each group. All statis-
tical analyses were performed in SPSS 20.0 (IBM Corp,
Armonk, NY, USA).
Results
A total of 178 patients were randomized to either the
intervention or the control group (Figure 1). Most of
the patients who were not eligible were postoperative
cardiac surgery patients with an expected length of stay
(LOS) <24 hours. One patient was incorrectly randomized
and did not receive a CGM device. Nine patients in the
intervention group and twelve patients in the control
group were excluded from analysis due to lack of CGM
data because of technical failure of the device, misplace-
ment of the sensor (n = 3) and problems with extraction
of the data (n = 18).
We performed a per protocol analysis from the data of
78 patients in each group. Table 1 shows the two groups,Figure 1 Flow chart of study participants: assessment, randomizationwhich were well matched with respect to all baseline
characteristics.
During the intervention, a total of 37,570 (intervention
group) and 32,957 (control group) CGM measurements
were collected. The number of reference arterial blood
gas glucose measurements was 1,599 in the intervention
group and 1,325 in the control group. The median num-
ber of additional calibrations needed for the CGM was
1.9 per 24 hours (IQR 1.2 to 3.3). The number of glucose
values entered in the PDMS (CGM measurements in the
intervention group and POC measurements in the con-
trol group) was 3,919 and 2,489 respectively.
Table 2 summarizes the outcome measures of the
study. The incidence of hypoglycemia (<2.2 mmol/L),
the primary safety endpoint, was similar in both the
intervention and the control group. None of the severe
hypoglycemic episodes detected by the CGM in the
intervention group was verified by arterial blood sam-
pling. In the control group, all severe hypoglycemic
episodes detected by the CGM, occurred in between two
POC glucose measurements and were not detected by
the nurses. In total, there were 14 patients (3 patients inand analysis.
Table 1 Baseline characteristics of participants
Intervention - CGM Control - POCM
(n = 87) (n = 90)
Age (years) 664 (14.0) 67.2 (11.4)
Women 45 (52%) 35 (39%)
BMI (kg/m2) 27.8 (7.0) 27.4 (5.8)
Weight (kg) 81.8 (21.7) 83.2 (21.5)
History of diabetes* 18 (21%) 21 (23%)
History of renal failure** 10 (12%) 5 (6%)
Reason for ICU admission
Surgical
Elective 19 (22%) 16 (18%)
Emergency 12 (14%) 13 (14%)
Medical 56 (64%) 61 (68%)
Admission diagnosis
Post cardiac surgery 12 (14%) 11 (12%)
Severe sepsis/septic shock 23 (26%) 18 (20%)
Pneumonia 12 (14%) 11 (12%)
Cardiac failure 10 (12%) 9 (10%)
COPD 3 (3%) 8 (9%)
Hemorrhagic shock 7 (8%) 10 (11%)
Cardiac arrest/resuscitation 10 (12%) 14(16%)
Other 10 (12%) 9 (10%)
APACHE IV predicted
mortality (%)
32 (10-70) 31 (20-60)
SOFA score on admission 8 (6-10) 7 (6-10)
Blood glucose level on
admission (mmol/L)
9.0 (2.6) 9.2 (2.5)
Mechanical ventilation 80 (92%) 83 (92%)
Data are mean (SD), median (IQR) or n (%). *Diabetes was defined as present
when this diagnosis was mentioned in the medical history; **renal failure was
present when the preadmission serum creatinine was above 177umol/l. CGM:
continuous glucose monitoring, POCM: point-of-care monitoring, BMI: body
mass index, ICU: intensive care unit, SOFA: sequential organ failure assessment,
COPD: chronic obstructive pulmonary disease; APACHE: acute physiology and
chronic health evaluation.






(n = 78) (n = 78)





Number of subjects 3 (4%) 4 (5%) 1.0
Episodes < 2.2 mmol/L 3 4
% of time for the reference
glucose level (SD)3
In target range (5.0-9.0 mmol/L) 69 (26) 66 (26) 0.47
Below target range
(2.2-5.0 mmol/L)
5 (7) 3 (5) 0.21
Mild/moderate hypoglycemia
(2.2-3.9)
1 (3) 0 (1) 0.03
Above target range (>9.0 mmol/L) 28 (26) 34 (27) 0.06
Mild/moderate hyperglycemia
(9.0-11.1)
17 (16) 26 (23) 0.01
Hyperglycemia (>11.1) 11(19) 7(14) 0.19
% of time for the sensor glucose
levels (SD)3
In target range (5.0-9.0 mmol/L) 75 (18) 71 (20) 0.18
Below target range
(2.2-5.0 mmol/L)
11 (13) 9 (12) 0.44
Mild/moderate hypoglycemia
(2.2-3.9)
2 (7) 1 (2) 0.14
Above target range (>9.0 mmol/L) 15 (16) 20 (21) 0.06
Mild/moderate hyperglycemia
(9.0-11.1)
12 (11) 16 (16) 0.03
Hyperglycemia (>11.1) 3 (7) 4 (9) 0.35
Mean reference blood glucose
(mmol/L)
8.2 (1.6) 8.3 (1.3) 0.53
Mean sensor glucose (mmol/L) 7.1 (1.1) 7.5 (1.3) 0.07
MAG change (mmol/L/h)2 0.33 (0.2-0.5) 0.32(0.2-0.4) 0.31
LOS ICU (hours) 137 (71-250) 95 (51-157) 0.04
LOS hospital (days) 15 (8-270) 14 (8-31) 0.91
Mortality ICU 15 (19%) 12 (15%) 0.67
Mortality hospital 22 (28%) 17 (22%) 0.46
Data shown are mean (SD), median (IQR), or n (%). 1Patients who experienced at
least one severe hypo- or hyperglycemic episode, verified by blood gas analysis;
2when at least three reference glucose measurements were available (intervention
n = 73, control n= 71); 3percentages do not add up to 100 due to rounding off.
CGM: continuous glucose monitoring; POCM: point-of-care measurement, MAG:
mean absolute glucose change; LOS: length of stay; ICU: intensive care unit.
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group) who experienced 19 ‘true’ hypoglycemic events
(<3.9 mmol/L) detected by ABL. Twenty-five percent
(n = 4) of the true ‘hypoglycemic’ events in the CGM
group and 67% (n = 2) in the control group were also
identified by CGM or POC (difference in glucose ≤10%).
All other endpoints such as percentage time in target
range, below target range, mean reference and sensor glu-
cose, glucose variability, hospital LOS, ICU and hospital
mortality were nonsignificantly different between the study
groups. Moderate hyperglycemia (9.0 to 11.1 mmol/L) was
significantly different in favor of the intervention group
(P = 0.03). A total of 355 time-linked reference glucose
CGM samples and 85 time-linked reference glucose POC
samples were used to assess accuracy of the devices.Median (IQR) RAD of the POC device was 7.1% (3 to 12)
whereas the median RAD of the CGM device was 13.7%
(8 to 23) (P <0.001). Bland-Altman plots per glucose mon-
itoring system are shown in an additional file (Figure S1 in
Additional file 1).
Table 3 summarizes nursing workload data per 24 hours.
The first column displays the average time burden per











POC measurement 3 12 (8) 36 (24) 0.06 (0.4) 0.2 (0.4)
Sensor CGM placement 3.5 - - 1 3.5
Sensor CGM calibration 2.5 - - 1.9 (1.2-3.3) 8 (11)
Sensor CGM data to enter in PDMS 0.3 - - 18 (10) 5.3 (3)
Total time (min) 36 (24) 17 (12)*
Data are expressed as mean (SD), or median (IQR). *P <0.001 in comparison with control group. POC: point-of-care; CGM: continuous glucose monitoring; PDMS:
patient data management system.
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for glucose control was significantly lower in the inter-
vention group compared to the control group (17 minutes
versus 36 minutes; P <0.001). The mean reduction in total
nursing workload was 19 minutes per 24 hours or 53% in
favour of the intervention group. As in this study, an open
blood drawing system was used, 5 mL blood per POC
measurement or calibration was taken from the patient.
Blood loss was therefore significantly reduced in the inter-
vention group (15.3 mL versus 60 mL per day; P <0.001).
The economic analysis of both groups is shown in
Table 4. The intervention group generated an average
total daily cost of EUR 41, whereas the total daily
cost in the control group was EUR 53. The difference
in costs was EUR −12 in favor of the intervention group
(95% CI −32 to −18, P = 0.02). The extra costs of the
CGM devices in the intervention group were neutralized
by the diminished costs for nursing personnel, material
and laboratory costs.
Discussion
The present study showed that a subcutaneous CGM
system to guide blood glucose regulation was equally ef-
fective and safe in glycemic control compared to frequent
POC-guided blood glucose regulation. However, CGM
significantly reduces nursing workload, blood loss and the
daily costs for glucose control.Table 4 Cost analysis




Nursing time €38/hr 36 min €22.98
CGM receiver €1009.59 - -
CGM sensor €61.00 - -
CGM calibration4 €1.19 - -
Accu-Chek Inform II device €892.37 €1.22 per day2 €1.22
Material POC measurement5 €0.70 12.2 €8.51
Laboratory6 €1.66 12.2 €20.18
Total costs €52.89
Factors and costs are expressed as means per patient per day (24 hours). 195% con
lifetime of two years; 3assuming a manufacturers’ sensor lifetime of two and a half
alcohol, cap (used for blood sampling) and testing strip POC; 6costs for a single poi
POC: point-of-care.Comparison with other studies
This is the second but largest randomized controlled trial
in which CGM is used to guide glycemic control in critic-
ally ill patients. In contrast to our findings, Holzinger and
colleagues did find less severe hypoglycemia in the CGM
group [16]. This may be caused by the very low incidence
of severe hypoglycemia in the present study, which was
true for both the intervention and the control group. This
may be related to a change of policy after the publication
of the NICE-SUGAR trial [4], which was a reason for our
and most other ICUs to increase their blood glucose tar-
get range. The increased target range may have reduced
the incidence of hypoglycemic events [19,20]. Indeed, the
blood glucose target used in the current study (5.0 to
9.0 mmol/L) was higher than in the Holzinger trial [16]
(4.4 to 6.1 mmol/L) and this is reflected in the achieved
mean blood glucose levels (8.1 vs. 6.3 mmol/L). Moreover,
the use of a fully computerized algorithm for glucose con-
trol and the high familiarity of the protocol among our IC
nurses may have contributed to the low incidence of
severe hypoglycemia. The available studies to date on tight
glucose control showed an increase in nursing workload
[21-23]. The potential benefits of CGM in the reduction
of blood samples, blood loss and nursing workload was
assumed in previous studies, but was not systematically
assessed before. We now observed that CGM significantly






17 min €10.87 €-12.11(−16, −9)
€1.38 per day2 €1.38 €1.38
€24.40 per day3 €24.40 €24.40
3.3 €3.95 €3.95 (3,5)
- - €-1.22
0.06 €0.04 €-8.47 (−10, −7)
0.06 €0.10 €-20.08 (−23, −18)
€40.74 €-12.42 (−22, −5)
fidence interval based on 1,000 stratified bootstrap samples; 2assuming a
days; 4calibration strip CGM; 5includes syringes, nonsterile gloves, gauzes,
nt-of-care glucose measurement. CGM: continuous glucose monitoring,
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finding seems clinically relevant, especially in a busy clin-
ical IC environment. Two studies focused on the cumu-
lative nursing workload accompanied with tight glucose
control protocols [21,22]. Gartemann et al. estimated
that nurses devoted approximately 42 minutes during
a 12-hour shift of their time to administering a tight
glycemic control (TGC) protocol, whereas Aragon et al.
even reported that up to 2 hours might be required for
tight glycemic control for a single patient in a 24-hour
period. In our POC control group, the mean nursing
workload estimate was less (36 minutes per 24 hours) than
the published estimates reported by other groups. This
might partly be explained by the use of a fully computer-
ized algorithm for glucose control in our ICU. In addition,
the familiarity of the protocol is very high among our
ICU nurses.
Effectiveness and costs
The use of CGM did not achieve improved glycemic
control in our study. We found similar percentages of
time-in-target and below-target range between the study
groups. The not-significantly lower percentage of time in
the hyperglycemic range in the intervention group could
be explained by the fact that CGM measurements were
more frequently entered in the glucose protocol than
POC measurements in the control group. This probably
resulted in more adjustments in the insulin treatment
with lower blood glucose levels as a consequence. The
significantly increased ICU LOS, which was observed in
the intervention group, may be a coincidence or reflect
unmeasured case-mix factors but is, in our view, unre-
lated to the glucose measurement strategy.
In contrast to our expectations, the cost analysis
shows that the use of CGM systems for glucose control
in an ICU setting is not a priori an expense. However,
we should be cautious in interpreting these results due
to the rather short time horizon (24 hours) in the analysis
of costs determination and the single-centre study design.
Also, cost savings cannot immediately be monetized due
to the short time horizon used in this cost analysis.
Accuracy of the subcutaneous measurements
The subcutaneous Freestyle Navigator CGM device that
we used in the present study showed a median RAD of
13.7%, which is higher than the 10.6 and 11.6% that was
found in previous validation studies of this device in crit-
ically ill patients, suggesting an accuracy acceptable for
clinical use. [11,14]. The lag time that may be needed for
the subcutaneous compartment to adapt to the intraven-
ous compartment appeared not to be clinically relevant
[11]. However, the accuracy as assessed in the current
study seems to indicate a need for improvement, because
the accuracy was less than the accuracy of the Accu-Chekand because a substantial number (75% in the CGM group
and 33% in the control group) of hypoglycemic events was
not detected. Of note, Leelarathna et al. [24] recently
investigated whether there was a difference in accuracy of
the Freestyle Navigator in a critical care setting using two
methods of calibration: (1) calibration according to the
manufacturer’s instructions (1, 2, 10, and 24 h) or (2) cali-
bration at variable intervals of 1 to 6 h using ABG. Using
enhanced calibration, at a median (interquartile range)
every 169 (122 to 213) minutes, the absolute relative devi-
ation was lower (7.0% (3.5, 13.0) vs. 12.8% (6.3, 21.8),
P <0.001). So, further significant improvements in ac-
curacy may be obtained by frequent calibrations with
ABG measurements. In the current study forced calibra-
tion was not possible, calibration was only performed
when the CGM device indicated the need for calibration
by itself.
In addition, technical problems with the subcutaneous
CGM device were observed during the study and led to
a 12% dropout. The most important reason was the tem-
porary loss of sensor signal from several minutes to
hours that resulted in a loss of data. Difficulties in the
calibration process were also identified as the CGM
could only be calibrated if the system indicated a calibra-
tion by itself, which occurred for median 1.9 times per
24 hours. Most of the technical difficulties, however,
may have been due to lack of experience working with
the CGM device despite the training of all ICU nurses.
We expect such problems to be easily resolved with add-
itional training and with the improved next generation
Freestyle Navigator II, which has recently been intro-
duced and showed good utility and sensor performance
in critically ill patients [25]. This study aimed to define
safety, efficacy and costs and therefore we neglected the
system dropout at this moment. It is true, however, that
this device can only become part of routine care when
the dropout percentage diminishes.
Strengths and weaknesses
The strengths of our study include the relatively large
sample size, the randomised controlled study design and
the wide variety in case mix. However, some limitations
of the present study merit further consideration. First,
the study was performed in a single Dutch intensive care
unit, which limits the generalizability of the study. Sec-
ond, the study was designed to blind the values of the
CGM in the control group. However, the CGM needed
to be calibrated several times during the study period,
which made it impossible to blind it completely. Third,
the nursing staff did not verify the severe hypoglycemia
that was indicated by CGM in two of the three patients
despite specific instructions to do so. One of these two
patients had evolved into a ‘withholding care policy’,
which was the reason to accept the severe hypoglycemia.
Boom et al. Critical Care 2014, 18:453 Page 8 of 9
http://ccforum.com/content/18/5/453We assume that in the other patient priority was given
to other important nursing tasks. Thus, the available
data are insufficient to define the accuracy of the CGM
in the hypoglycemic range. In our previous studies this
was not identified as a clinical problem [11,14]. Also,
with an adapted algorithm, the CGM should be able to
detect a decreasing glucose level before hypoglycemia is
present and give a timely alert. Fourth, the computerized
algorithm was designed for intermittent POC measure-
ments and not for (semi-) continuous data. As such, the
patients did not fully benefit from the frequent glucose
measurements by CGM. An algorithm based on 10-
minute glucose input might have led to other results. We
did identify this issue beforehand but we decided to keep
the algorithm for both groups the same to be able to in-
vestigate the contribution of CGM per se. It can be ex-
pected that an adapted algorithm will further improve the
performance of CGM in the guidance of glycemic control.
Conclusions
Subcutaneous CGM to guide blood glucose regulation in
critically ill patients was shown to be safe in terms of
hypoglycemia incidence. With an identical insulin treat-
ment algorithm, the CGM was equally effective as POC
measurement. A new algorithm designed for frequent
measurements may further improve the results and
should precede clinical implementation. CGM signifi-
cantly reduced nursing workload, blood loss and the
daily costs for glucose control.
Key messages
 Insulin treatment based on continuous
subcutaneous glucose monitoring (CGM) revealed
the same number of hypoglycemic events compared
to point of care (POC)
 Subcutaneous CGM was equally effective as POC
measured as glucose time in target range
 Total costs were lower when using subcutaneous
CGM than frequent POC
 Nursing workload with glucose regulation was reduced
by subcutaneous CGM compared to frequent POC
 A new algorithm designed for continuous
measurement should be developed before CGM can
be implemented clinicallyAdditional file
Additional file 1: Figure S1. Bland-Altman plots per glucose
monitoring system (A), CGM system (Freestyle Navigator) (B), point-of-care
measurement (Accu-Chek). The x-axis represents the average of the sensor
or device and reference glucose values in mmol/l. The y-axis represents the
absolute difference between sensor or device and reference glucose values
in mmol/l. The dotted lines represent the 5th and 95th percentile.Competing interests
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